Targeting Chitinase 1 and Chitinase 3-Like 1 as Novel Therapeutic Strategy of Pulmonary Fibrosis.

Targeting Chitinase 1 and Chitinase 3-Like 1 as Novel Therapeutic Strategy of Pulmonary Fibrosis.
复制标题

DOI:
10.3389/fphar.2022.826471
复制
发表时间:
2022
影响因子:
5.6
通讯作者:
Lee CG
Lee CG
中科院分区:
医学2区
文献类型:
--
作者:
Lee SY;Lee CM;Ma B;Kamle S;Elias JA;Zhou Y;Lee CG

文献摘要

参考文献

被引文献

相似文献

几丁质酶1(Chitinase 1,CHIT 1)和几丁质酶3-like-1(chitinase 3-like-1,CHI 3L 1)是18-糖基水解酶家族的两个代表性成员,与多种以炎症和重塑为特征的人类疾病的发病机制密切相关。值得注意的是,在肺纤维化患者中注意到CHIT 1和CHI 3L 1的表达失调,并且它们的水平与患者的临床结果呈负相关。CHIT 1和CHI 3L 1主要在肺泡巨噬细胞中表达,调节促纤维化巨噬细胞活化、成纤维细胞增殖和肌成纤维细胞转化以及TGF-β信号传导和效应器功能。虽然CHIT 1和CHI 3L 1用于调节肺纤维化的机制或途径尚未完全了解,但这些研究将CHIT 1和CHI 3L 1鉴定为导致持续性和进行性肺纤维化的纤维增生反应的重要调节剂。这些研究表明,CHIT 1和CHI 3L 1可能是干预或逆转已建立的肺纤维化的合理治疗靶点。在这篇综述中,我们将讨论CHIT 1和CHI 3L 1作为肺纤维化新治疗靶点在促纤维化细胞和组织反应中的具体作用和调节机制。
Chitinase 1 (CHIT1) and chitinase 3-like-1 (CHI3L1), two representative members of 18-Glycosyl hydrolases family, are significantly implicated in the pathogenesis of various human diseases characterized by inflammation and remodeling. Notably, dysregulated expression of CHIT1 and CHI3L1 was noted in the patients with pulmonary fibrosis and their levels were inversely correlated with clinical outcome of the patients. CHIT1 and CHI3L1, mainly expressed in alveolar macrophages, regulate profibrotic macrophage activation, fibroblast proliferation and myofibroblast transformation, and TGF-β signaling and effector function. Although the mechanism or the pathways that CHIT1 and CHI3L1 use to regulate pulmonary fibrosis have not been fully understood yet, these studies identify CHIT1 and CHI3L1 as significant modulators of fibroproliferative responses leading to persistent and progressive pulmonary fibrosis. These studies suggest a possibility that CHIT1 and CHI3L1 could be reasonable therapeutic targets to intervene or reverse established pulmonary fibrosis. In this review, we will discuss specific roles and regulatory mechanisms of CHIT1 and CHI3L1 in profibrotic cell and tissue responses as novel therapeutic targets of pulmonary fibrosis.
DOI: 10.1016/j.ebiom.2021.103373
发表时间: 2021-05
期刊: EBioMedicine
影响因子: 11.1
作者:
Strykowski R;Adegunsoye A
通讯作者: Adegunsoye A
DOI: 10.1164/rccm.200906-0964oc
发表时间: 2010-03-15
影响因子: 24.7
作者:
Daniels, Craig E.;Lasky, Joseph A.;Schroeder, Darrell R.
通讯作者: Schroeder, Darrell R.
DOI: 10.1038/ncomms12564
发表时间: 2016-08-18
影响因子: 16.6
作者:
Chen H;Qu J;Huang X;Kurundkar A;Zhu L;Yang N;Venado A;Ding Q;Liu G;Antony VB;Thannickal VJ;Zhou Y
通讯作者: Zhou Y
DOI: 10.1016/j.mam.2018.08.004
发表时间: 2019-03
影响因子: 10.6
作者:
Chanda D;Otoupalova E;Smith SR;Volckaert T;De Langhe SP;Thannickal VJ
通讯作者: Thannickal VJ
DOI: 10.1016/j.rmed.2010.02.026
发表时间: 2010-08-01
影响因子: 4.3
作者:
Furuhashi, Kazuki;Suda, Takafumi;Chida, Kingo
通讯作者: Chida, Kingo